
Celgene’s Abraxane combo flops in phase 3 cancer trials
pharmafile | March 14, 2019 | News story | Research and Development | Abraxane, Celgene, clinical trials, pharma, trials
Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients with pancreatic cancer.
Celgene’s drug failed to achieve its primary endpoint of improvement in disease-free survival in patients with surgically resected pancreatic adenocarcinoma, as confirmed by independent radiological review, compared to gemcitabine alone.
The randomised ‘apact’ study of 866 patients tested Abraxane in combination with gemcitabine against gemcitabine alone. The difference between the two treatments was not found to be significant.
“Overall survival, a secondary endpoint of the study, was improved, reaching nominal statistical significance,” a statement from Celgene said.
“The Celgene-sponsored, pivotal, Phase 3 apact study evaluating the investigational use of Abraxane in combination with gemcitabine following surgical resection (adjuvant treatment) in patients with pancreatic cancer did not achieve the primary endpoint of improvement in disease-free survival,” the statement said.
Celgene confirmed Abraxane’s safety profile was in line with previous clinical data. Abraxane was previously authorised as a treatment for metastatic breast cancer in 2005, and later as a treatment for non-small-cell lung cancer and late-stage pancreatic cancer.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …






